Which treatments are commonly used for hypercalcemia of malignancy?

Which treatments are commonly used for hypercalcemia of malignancy?

• A. IV fluids, calcitonin, bisphosphonates, glucocorticoids
• B. Diuretics, alkalinization, chemo
• C. Potassium-sparing diuretics, calcium supplements
• D. Radiation therapy alone

Answer: (A)

The main idea is how to rapidly and effectively lower calcium in hypercalcemia of malignancy while also addressing the cancer driving it. Start with aggressive IV isotonic fluids to correct fluid volume depletion and promote calciuresis, which begins the process of lowering serum calcium. Calcitonin provides a quick, short-term dip in calcium by inhibiting osteoclast activity and increasing renal calcium excretion, giving a rapid but transient benefit. For longer-lasting control, bisphosphonates are used because they suppress osteoclast-mediated bone resorption; their effect builds over 24 to 72 hours and can last days to weeks, making them the mainstay for sustained reduction. Glucocorticoids are particularly useful when the hypercalcemia is related to certain cancers or vitamin D–mediated processes, as they reduce intestinal calcium absorption and can enhance calcium loss in specific malignancies. Together, these therapies address both the immediate reduction of calcium and the ongoing control needed to manage malignancy-driven hypercalcemia. Diuretics and alkalinization aren’t first-line for acute management; diuretics may have a role only after proper hydration and with careful monitoring, and alkalinization is not a beneficial strategy for this condition. Radiation therapy isn’t a rapid fix for hypercalcemia, though it may help with bone-related symptoms or tumor control in certain cases.

The main idea is how to rapidly and effectively lower calcium in hypercalcemia of malignancy while also addressing the cancer driving it. Start with aggressive IV isotonic fluids to correct fluid volume depletion and promote calciuresis, which begins the process of lowering serum calcium. Calcitonin provides a quick, short-term dip in calcium by inhibiting osteoclast activity and increasing renal calcium excretion, giving a rapid but transient benefit. For longer-lasting control, bisphosphonates are used because they suppress osteoclast-mediated bone resorption; their effect builds over 24 to 72 hours and can last days to weeks, making them the mainstay for sustained reduction. Glucocorticoids are particularly useful when the hypercalcemia is related to certain cancers or vitamin D–mediated processes, as they reduce intestinal calcium absorption and can enhance calcium loss in specific malignancies. Together, these therapies address both the immediate reduction of calcium and the ongoing control needed to manage malignancy-driven hypercalcemia.

Diuretics and alkalinization aren’t first-line for acute management; diuretics may have a role only after proper hydration and with careful monitoring, and alkalinization is not a beneficial strategy for this condition. Radiation therapy isn’t a rapid fix for hypercalcemia, though it may help with bone-related symptoms or tumor control in certain cases.